Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 37, Issue 7, 2006, Pages 699-708

  Sohn, S K ^a   Kim, D H ^a   Baek, J H ^a   Kim, J G ^a   Lee, K B ^a   Lee, K H ^b   Lee, J H ^b   Choi, S J ^b   Shin, I H ^c  

^a Kyungpook National University Hospital   (South Korea)

^b University of Ulsan   (South Korea)

^c Catholic University of Daegu   (South Korea)

Author keywords

Acute graft versus host disease; Allogeneic stem cell transplantation; Chronic graft versus host disease; Progressive or quiescent type

Indexed keywords

ACICLOVIR; ALKALINE PHOSPHATASE; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; LYMPHOCYTE ANTIBODY; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THALIDOMIDE; THYMOCYTE ANTIBODY; TSUKUBAENOLIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION COMPLICATION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE;

ACUTE DISEASE; ADOLESCENT; ADULT; CHRONIC DISEASE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SIBLINGS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33645221804     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705313     Document Type: Article

References (22)

1. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215-233.
2. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
3. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001; 97: 1196-1201.
4. Lee JH, Choi SJ, Kim S, Seol M, Lee YS, Lee JS et al. Graft-versus-host disease (GVHD)-specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation. Br J Haematol 2003; 122: 637-644.
5. Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S et al. Performance of a new clinical grading system for chronic graft-versus-host disease: A multicenter study. Blood 2003; 102: 802-809.
6. Lee KH, Choi SJ, Lee JH, Lee JS, Kim WK, Lee KB et al. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica 2005; 90: 939-948.
7. Sohn SK, Kim DH, Kim JG, Lee NY, Suh JS, Lee KS et al. Transplantation outcome in allogeneic PBSCT patients according to a new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset. Bone Marrow Transplant 2004; 34: 63-68.
8. Kim DH, Kim JG, Sohn SK, Sung WJ, Suh JS, Lee KS et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 2004; 125: 217-224.
9. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
10. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol 2004; 125: 435-454.
11. Akpek G, Zahurak ML, Piantadosi S, Margolis J, Doherty J, Davidson R et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97: 1219-1226.
12. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al. Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse. Blood 2002; 100: 406-414.
13. Perruche S, Kleinclauss F, Tiberghien P, Saas P. B Cell allogeneic responses after hematopoietic cell transplantation: Is it time to address this issue? Transplantation 2005; 79 (3 Suppl): S37-S39.
14. Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: Clinical manifestation and therapy. Bone Marrow Transplant 2001; 28: 121-129.
15. Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine J, Yanik G et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000; 133: 275-279.
16. Remberger M, Kumlien G, Aschan J, Barkholt L, Hentschke P, Ljungman P et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 674-682.
17. Krenger W, Falzarano G, Delmonte Jr J, Snyder KM, Byon JC, Ferrara JL et al. Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood 1996; 88: 1113-1121.
18. Jadus MR, Wepsic HT. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant 1992; 10: 1-14.
19. Broxmeyer HE, Williams DE, Lu L, Cooper S, Anderson SL, Beyer GS et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: Synergism of tumor necrosis factor and interferon-gamma. J Immunol 1986; 136: 4487-4495.
20. Wakae T, Takatsuka H, Seto Y, Iwata N, Mori A, Okada M et al. Similarity between hepatic graft-versus-host disease and primary biliary cirrhosis. Hematology 2002; 7: 305-310.
21. Serody JS, Burkett SE, Panoskaltsis-Mortari A, Ng-Cashin J, McMahon E, Matsushima GK et al. T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 2000; 96: 2973-2980.
22. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versus-host disease. Blood 2005; 105: 4191-4199.